Inovio Pharmaceuticals Stock Earnings Reports
INO Upcoming Earnings (Q3 2023)
Earnings Date: | Nov 06, 2023 |
Consensus EPS: | Premium |
Current P/E* ratio: 0 | Price (Sep 20, 2023, EOD): $0.390
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for INO Premium
FAQ
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery o... INO Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.